Top

Published in:

01-12-2006 | Review

Pathology of primary malignant bone and cartilage tumours

Authors: L. B. Rozeman, A. M. Cleton-Jansen, P. C. W. Hogendoorn

Published in: International Orthopaedics | Issue 6/2006

Abstract

Bone- and cartilage-forming tumours (osteosarcomas and chondrosarcomas) are rare malignant neoplasms. These tumours are clinically aggressive and often need extensive local and/or systemic treatment. Whereas no other treatment but surgery is currently available for chondrosarcomas, osteosarcomas show an approximately 50–80% response rate to adjuvant chemotherapy. Surgical removal of these tumours is currently mostly performed with limb salvage, but amputation may be required in some cases. In addition, the tumours have a risk of local recurrences adversely affecting the prognosis compared to the primary tumour. In this report we will mainly focus on two of the most prevalent malignant bone tumours, conventional osteosarcoma and conventional chondrosarcoma, and use these to illustrate the problems with the diagnosis of bone sarcomas in general.

Anninga JK, Van de Vijver MJ, Cleton-Jansen AM, Kristel PMP, Taminiau AHM, Nooij M, Egeler RM, Hogendoorn PCW (2004) Overexpression of the Her-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 40:963–970PubMedCrossRef

Bertoni F, Bacchini P, Hogendoorn PCW (2002) Chondrosarcoma. In: Fletcher CDM, Unni KK, Mertens F (eds) World Health Organisation classification of tumours. Pathology and genetics of tumours of soft tissue and bone. IARC Press, Lyon, pp 247–251

Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jurgens H, Winkler K (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols. J Clin Oncol 20:776–790PubMedCrossRef

Bovée JVMG, Cleton-Jansen AM, Rosenberg C, Taminiau AHM, Cornelisse CJ, Hogendoorn PCW (1999) Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis. J Pathol 189:454–462PubMedCrossRef

Bovée JVMG, Cleton-Jansen AM, Taminiau AHM, Hogendoorn PCW (2005) Emerging pathways in the development of chondrosarcoma of bone and the implications for targeted treatment. Lancet Oncol 6:599–607PubMedCrossRef

Bovée JVMG, Royen Mv, Bardoel AFJ, Rosenberg C, Cornelisse CJ, Cleton-Jansen AM, Hogendoorn PCW (2000) Near-haploidy and subsequent polyploidization characterize the progression of peripheral chondrosarcoma. Am J Pathol 157:1587–1595PubMed

Burak Z, Moretti JL, Ersoy O, Sanli U, Kantar M, Tamgac F, Basdemir G (2003) 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression. J Nucl Med 44:1394–1401PubMed

Chow WA, Bedell V, Gaytan P, Borden E, Goldblum J, Hicks D, Slovak ML (2006) Methylthioadenosine phosphorylase gene deletions are frequently detected by fluorescence in situ hybridization in conventional chondrosarcomas. Cancer Genet Cytogenet 166:95–100PubMedCrossRef

Cleton-Jansen AM, van Beerendonk HM, Baelde HJ, Bovée JVMG, Karperien M, Hogendoorn PCW (2005) Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma. Clin Cancer Res 11:8028–8035PubMedCrossRef

10.

Cleton-Jansen AM, Buerger H, Hogendoorn PCW (2005) Central high-grade osteosarcoma of bone: diagnostic and genetic considerations. Curr Diagn Pathol 11:390–399CrossRef

11.

Dietlein M, Féaux de Lacroix W, Neufang KFR, Steinbrich W, Schmidt J (1990) Zur Problematik der Dignitätsbeurteilung von Knorpeltumoren langer Rohrenknochen aus radiologischer und pathologischer Sicht. Rontgen Blatt 174:180

12.

Evans HL, Ayala AG, Romsdahl MM (1977) Prognostic factors in chondrosarcoma of bone. A clinicopathologic analysis with emphasis on histologic grading. Cancer 40:818–831PubMedCrossRef

13.

Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J, O’Reilly T, Traxler P, Chaudhuri B, Fretz H, Zimmermann J, Meyer T, Caravatti G, Furet P, Manley PW (2002) Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther 93:79–98PubMedCrossRef

14.

Fuchs B, Pritchard DJ (2002) Etiology of osteosarcoma. Clin Orthop Relat Res :40–52

15.

Geirnaerdt MJ, Bloem JL, Eulderink F, Hogendoorn PCW, Taminiau AHM (1993) Cartilaginous tumors: correlation of gadolinium-enhanced MR imaging and histopathologic findings. Radiology 186:813–817PubMed

16.

Geirnaerdt MJ, Hogendoorn PCW, Bloem JL, Taminiau AHM, Van der Woude HJ (2000) Cartilaginous tumors: fast contrast-enhanced MR imaging. Radiology 214:539–546PubMed

17.

Geirnaerdt MJA, Hermans J, Bloem JL, Kroon HM, Pope TL, Taminiau AHM, Hogendoorn PCW (1997) Usefulness of radiography in differentiating enchondroma from central grade I chondrosarcoma. A J R 169:1097–1104

18.

Hauben EI, Arends J, Vandenbroucke JP, van Asperen CJ, Van Marck E, Hogendoorn PC (2003) Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma. Eur J Hum Genet 11:611–618PubMedCrossRef

19.

Hauben EI, Bielack S, Grimer R, Jundt G, Reichardt P, Sydes M, Taminiau AH, Hogendoorn PC (2006) Clinico-histologic parameters of osteosarcoma patients with late relapse. Eur J Cancer 42:460–466PubMedCrossRef

20.

Hauben EI, Weeden S, Pringle J, Van Marck EA, Hogendoorn PC (2002) Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer 38:1218–1225PubMedCrossRef

21.

Hogendoorn PCW, Bovée JVMG, Karperien M, Cleton-Jansen AM (2003) Skeletogenesis: genetics. In: Cooper DN (ed) Nature encyclopedia of the human genome. Nature Publishing Group, London, pp 306–313

22.

Huvos AG (1991) Bone tumors. Diagnosis, treatment, and prognosis, 2nd edn. W.B. Saunders Company, Philadelphia

23.

Jiang X, Dutton CM, Qi W, Block JA, Brodt P, Durko M, Scully SP (2003) Inhibition of MMP-1 expression by antisense RNA decreases invasiveness of human chondrosarcoma. J Orthop Res 21:1063–1070PubMedCrossRef

24.

Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM, Helman LJ (2004) The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10:182–186PubMedCrossRef

25.

Lagonigro MS, Tamborini E, Negri T, Staurengo S, Dagrada GP, Miselli F, Gabanti E, Greco A, Casali PG, Carbone A, Pierotti MA, Pilotti S (2006) PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma. J Pathol 208:615–623PubMedCrossRef

26.

Link MP, Gebhardt MC, Meyers PA (2002) Osteosarcoma. In: Pizzo PA, Poplack DG (eds) Principles and practice of pediatric oncology. Lippincott, Williams & Wilkins, Philadelphia, pp 1502–1589

27.

Marina N, Gebhardt M, Teot L, Gorlick R (2004) Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9:422–441PubMedCrossRef

28.

McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, Fidler IJ, Bar-Eli M (2002) Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 8:3584–3591PubMed

29.

Mirra JM, Gold R, Downs J, Eckardt JJ (1985) A new histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones. A clinicopathologic analysis of 51 cases. Clin Orthop :214–237

30.

Miyaji T, Nakase T, Onuma E, Sato K, Myoui A, Tomita T, Joyama S, Ariga K, Hashimoto J, Ueda T, Yoshikawa H (2003) Monoclonal antibody to parathyroid hormone-related protein induces differentiation and apoptosis of chondrosarcoma cells. Cancer Lett 199:147–155PubMedCrossRef

31.

Morioka H, Weissbach L, Vogel T, Nielsen GP, Faircloth GT, Shao L, Hornicek FJ (2003) Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clin Cancer Res 9:1211–1217PubMed

32.

O’Flanagan SJ, Stack JP, McGee HMJ, Dervan P, Hurson B (1991) Imaging of intramedullary tumour spread in osteosarcoma. A comparison of techniques. J Bone Jt Surg [Br] 73B:998–1001

33.

Rizzo M, Ghert MA, Harrelson JM, Scully SP (2001) Chondrosarcoma of bone: analysis of 108 cases and evaluation for predictors of outcome. Clin Orthop 391:224–233PubMed

34.

Schiller AL (1985) Diagnosis of borderline cartilage lesions of bone. Semin Diagn Pathol 2:42–62PubMed

35.

Van der Woude HJ, Bloem JL, Hogendoorn PCW (1998) Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing’s sarcoma: review of current imaging modalities. Skeletal Radiol 27:57–71PubMedCrossRef

Title: Pathology of primary malignant bone and cartilage tumours
Authors: L. B. Rozeman
A. M. Cleton-Jansen
P. C. W. Hogendoorn
Publication date: 01-12-2006
Publisher: Springer-Verlag
Published in: International Orthopaedics / Issue 6/2006
Print ISSN: 0341-2695
Electronic ISSN: 1432-5195
DOI: https://doi.org/10.1007/s00264-006-0212-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Pathology of primary malignant bone and cartilage tumours

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2006

Surgical treatment of giant cell tumour of long bone with anhydrous alcohol adjuvant

Deformity correction and lengthening of lower legs with an external fixator

Lower limb salvage surgery: modular endoprosthesis in bone tumour treatment

Role of staged endoprosthetic revision with flap cover for limb salvage in endoprosthetic failure

Massive allografts in tumour surgery

Bone tumours